Jun Lee

“I think I understand the medical rationale for narcolepsy patients taking both occipates and orexin agonists, but what sorts of evidence would you need to generate to convince the payers to reimburse for both premium price drugs, especially since the patients from both fibrins 1 and 2 seem to be doing well just on…”

“This is awesome one for June, just a couple from us. So are you eligible for priority review for the AXS-12 NDE submission? And I just want to make sure I understand correctly, Nick, you're saying that the growth to net availability should actually improve after approval given the Medicare population.”

“We're on for June, just a couple from us. So you said previously that the second pharmacy would have more meaningful contribution in the fourth quarter.”

“Regarding the $3 to $5 billion in peak sales opportunity for your hypercordialism franchise that mentioned on the call, how much of that is coming from Corlin? And given the pending approval of Rella Corlin, how important is it to you that you win on the ongoing appeals process with PEPA?”